Insulin Market - Global Industry Analysis

Market Overview

In terms of revenue, the global Insulin Market accounted for USD48,828 Million in 2020 and is expected to reach USD 73,632 Millionby 2028, growing at a CAGR of 5.3% from 2021 to 2028.

Globally, more than 422 million people are suffering from type 1and type 2 diabetes. Wherein, most of the insulin demand is comingfrom type 1 as they are needed to inject insulin on daily basis toregulate the blood sugar level and avoid any further complications.As of 2020, more than 10% of the diabetic population is affected byT1D and the number is expanding rapidly with each passing year. Allage groups around found to be affected by the disease, but theprevalence is relatively higher among elderly people. In fact,people having T2D for more than 20 years are also emerged as theconsumer of insulin on regular basis. 

Report Scope:

Over $760 billion was spent on diabetes management in 2019across the globe and the number is expected to surpass 830 billionby 2030 on account of rapidly growing prevalence of the disease.Wherein, the U.S. emerged as the largest country to spend more than$327 billion of diabetic care. The demand for insulin is likely toremain high in the developed countries of North America and Europeon account of its easy availability, controlled prices in Europe,coverage in insurance policy, and strong healthcare infrastructureamong others. China, India, the U.S. and Brazil are the top fourcountries housing largest diabetic population. For instance, Chinaalone has more than 116 million people suffering from the disease,whereas the U.S. has over 34 million people. In fact, it is thesixth deadliest disease across the globe. Every year, it claimslife of more than 1.8 million people.

The average price per unit across all types of insulin inAmerica was $98.70 (£76.34). Other countries would have paid afraction as much for the same insulins. American prices were foundto be 27.7 times higher than units sold in Turkey and 6.3 timeshigher than those in Canada, 5.9 times higher than those in Japanand 8.9 times higher than those in the U.K.

COVID-19 Impact Analysis

Covid-19 pandemic has impacted all the sectors across the globe.However, it fails to leave any evident dent on the demand forinsulin. The demand remained steady during the initial period andis likely to continue the same in the years to come. However, thepandemic has disrupted the supply chain of materials required formanufacturing insulin to some extent due to stringent lockdownrestrictions across the globe. The lockdown has hampered thesmoothness of raw material transport to the manufacturing facility,which, in turn, has created pressure on the available resources tomeet the increasing demand for the products. Most of the playersbased in the European and Asia Pacific region faced littledifficulty in accessing the raw materials due to the ban on theimport and export activities to reduce the spread of infection. Asa result, the manufacturers had to purchase the required materialfrom the local providers at inflated prices

Growth Factors

Globally more than 422 million people are living with diabetesacross the globe. Every year, more than 1.6 million people die ofthe disease. Wherein, the prevalence of diagnosis and mortality ishigher in aging population. Mid and low-income countries are theworst affected, especially in Asia, Africa and Latin America. By2040, the diabetic population is likely to double, which wouldfurther drive the demand for insulin. As of 2019, Latin had around2.9 million people using insulin on daily basis, which is likely togrow at an alarming rate in the years to come.

The global market is witnessing a significant growth in theprevalence of diabetes on account of changing lifestyle, increasingobese and overweight population, sedentary lifestyle, increasedconsumption of food containing higher amount of carbohydrates andfat, and growing hereditary prevalence of type diabetes. Over 39%of the global adults are categorized as overweight. In 2016, morethan 1.9 billion adults, 18 years and older, were overweight. Ofthese over 650 million were obese. Apart from this, large number ofpeople are consuming tobacco and smoking. The number issignificantly high in China and India. It further increases therisk of developing diabetes.

Report Scope:

Type Segment Analysis Preview:

On the basis of types the global market is segmented intoRapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, andPremixed. Rapid-acting insulin starts working somewhere between 2.5to 20 minutes after injection. Its action is at its greatestbetween one and three hours after injection and can last up to fivehours. This type of insulin acts more quickly after a meal, similarto the body's natural insulin, reducing the risk of a low bloodglucose (blood glucose below 4 mmol/L). Short-acting insulin takeslonger to start working than the rapid-acting insulins. It startsto reduce blood glucose levels within 30 minutes. Therefore, it isrecommended to administrate the dose within 30 minutes beforeeating. This type of insulin can last up to eight hours, but showsmaximum efficiency in the first 2-5 hours.

Indication Segment AnalysisPreview:

On the basis of Indication, the global market is segmented intotype 1 and type 2. It is recommended for the patient having type 1diabetes to inject insulin on daily basis. They are often advisedto take rapid insulin dose along with last lasting insulin forbetter outcome. Type 1 diabetes is always treated with insulin,which is injected with a pen, syringe or pump. The aim is to keepblood glucose levels as close to normal as possible. Over 64,000Americans are diagnosed with T1D every year. As of 2020, over 1.6million people in the U.S. are suffering from the disease.

Regional Analysis Preview

U.S. is projected to continue dominating the North Americainsulin market during the forecast period. Canada holdingsignificantly low share of the market as compared the U.S. As of2019, the country spent $327 billion on diabetes care. Each year,over 64,000 Americans are diagnosed with T1D and more than 1.64million people are living with the same disease in the country. In2018, over 10.5% of American population or 34.4 million haddiabetes. Wherein, the prevalence is significantly higher inelderly population having age above 60 years. To be precise, over14.3 million people with 65 years and above are suffering from thedisease.

Asia Pacific is housing over 60% of the global population, outof which, more than 35% is residing in China and India. Theprevalence of diabetes is significantly higher in low- andmid-income countries. China is housing the world largest populationsuffering from diabetes. Currently, China and India have over 116million and 77 million people suffering from diabetes,respectively. In addition to this, more than 50% of the globalpopulation having diabetes lives in Asia Pacific region.

Key Market Players & Competitive Landscape

Some of key players in Insulin Market are,

1. Novo Nordisk
2. Eli Lilly & Co.
3. Sanofi
4. Biocon

The Insulin Market is segmented as follows:

Type Segment Analysis

• Rapid-Acting
  • Glulisine
  • Lispro
  • Aspart
• Short-Acting
• Intermediate-Acting
• Long-Acting
  • Glargine
  • Detemir
• Premixed

Indication Segment Analysis

• Type 1
• Type 2

Global Mold Inhibitors Market: Regional SegmentAnalysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

• CHAPTER NO. 1: INTRODUCTION
  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. USP & Key Offerings
  • 1.2. Key Benefits for Stakehulders
  • 1.3. Target Audience
  • 1.4. Report Scope
• CHAPTER NO. 2: COVID 19 IMPACT ANALYSIS
  • 2.1. Impact Assessment of COVID-19 Pandemic, By Region
  • 2.2. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
  • 2.3. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
• CHAPTER NO. 3: INSULIN MARKET – TYPE SEGMENT ANALYSIS
  • 3.1. Overview
    • 3.1.1. Market Revenue Share, By Type, 2020 & 2028
  • 3.2. Rapid-Acting
    • 3.2.1. Key Market Trends, Growth Factors, & Opportunities
  • 3.3. Short-Acting
    • 3.3.1. Key Market Trends, Growth Factors, & Opportunities
  • 3.4. Intermediate-Acting
    • 3.4.1. Key Market Trends, Growth Factors, & Opportunities
  • 3.5. Long-Acting
  • 3.6. Premixed
    • 3.6.1. Key Market Trends, Growth Factors, & Opportunities
• CHAPTER NO. 4: RAPID-ACTING MARKET – TYPE SEGMENT ANALYSIS
  • 4.1. Overview
    • 4.1.1. Market Revenue Share, By Type, 2020 & 2028
  • 4.2. Glulisine
    • 4.2.1. Key Market Trends, Growth Factors, & Opportunities
  • 4.3. Lispro
    • 4.3.1. Key Market Trends, Growth Factors, & Opportunities
  • 4.4. Aspart
    • 4.4.1. Key Market Trends, Growth Factors, & Opportunities
• CHAPTER NO. 5: LONG-ACTING MARKET – TYPE SEGMENT ANALYSIS
  • 5.1. Overview
    • 5.1.1. Market Revenue Share, By Type, 2020 & 2028
  • 5.2. Glargine
    • 5.2.1. Key Market Trends, Growth Factors, & Opportunities
  • 5.3. Detemir
    • 5.3.1. Key Market Trends, Growth Factors, & Opportunities
• CHAPTER NO. 6: INSULIN MARKET – INDICATION SEGMENT ANALYSIS
  • 6.1. Overview
    • 6.1.1. Market Revenue Share, By Indication, 2020 & 2028
  • 6.2. Type 1
    • 6.2.1. Key Market Trends, Growth Factors, & Opportunities
  • 6.3. Type 2
    • 6.3.1. Key Market Trends, Growth Factors, & Opportunities
• CHAPTER NO. 7: INSULIN MARKET – REGIONAL ANALYSIS
  • 7.1. Overview
    • 7.1.1. Global Market Revenue Share, By Region, 2020 & 2028
    • 7.1.2. Global Market Vulume Share, By Region, 2020 & 2028
    • 7.1.3. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
    • 7.1.4. Global Market Vulume, By Region, 2016 – 2028 (Million Ml)
  • 7.2. North America
    • 7.2.1. North America Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.2.2. North America Insulin Market Vulume, By Country, 2016 – 2028 (Million Ml)
    • 7.2.3. North America Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.2.3.1. North America Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.2.3.2. North America Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
    • 7.2.4. North America Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.2.5. U.S.
      • 7.2.5.1. U.S. Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.2.5.2. U.S. Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.2.5.3. U.S. Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.2.5.4. U.S. Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.2.6. Canada
      • 7.2.6.1. Canada Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.2.6.2. Canada Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.2.6.3. Canada Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.2.6.4. Canada Insulin Market Revenue, By Indication, 2016 – 2028
  • 7.3. Europe
    • 7.3.1. Europe Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.3.2. Europe Insulin Market Vulume, By Country, 2016 – 2028 (Million Ml)
    • 7.3.3. Europe Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.3.1. Europe Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.3.2. Europe Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
    • 7.3.4. Europe Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.3.5. Germany
      • 7.3.5.1. Germany Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.5.2. Germany Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.5.3. Germany Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.5.4. Germany Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.3.6. France
      • 7.3.6.1. France Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.6.2. France Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.6.3. France Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.6.4. France Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.3.7. U.K
      • 7.3.7.1. U.K Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.7.2. U.K Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.7.3. U.K Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.7.4. U. K Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.3.8. Italy
      • 7.3.8.1. Italy Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.8.2. Italy Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.8.3. Italy Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.8.4. Italy Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.3.9. Spain
      • 7.3.9.1. Spain Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.9.2. Spain Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.9.3. Spain Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.9.4. Spain Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.3.10. Rest of Europe
      • 7.3.10.1. Rest of Europe Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.10.2. Rest of Europe Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.10.3. Rest of Europe Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.3.10.4. Rest of Europe Insulin Market Revenue, By Indication, 2016 – 2028
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.4.2. Asia Pacific Insulin Market Vulume, By Country, 2016 – 2028 (Million Ml)
    • 7.4.3. Asia Pacific Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.3.1. Asia Pacific Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.3.2. Asia Pacific Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
    • 7.4.4. Asia Pacific Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.4.5. China
      • 7.4.5.1. China Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.5.2. China Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.5.3. China Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.5.4. China Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.4.6. Korea
      • 7.4.6.1. Korea Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.6.2. Korea Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.6.3. Korea Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.6.4. Korea Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.4.7. India
      • 7.4.7.1. India Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.7.2. India Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.7.3. India Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.7.4. India Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.4.8. Japan
      • 7.4.8.1. Japan Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.8.2. Japan Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.8.3. Japan Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.8.4. Japan Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.4.9. Southeast Asia
      • 7.4.9.1. Southeast Asia Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.9.2. Southeast Asia Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.9.3. Southeast Asia Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.9.4. Southeast Asia Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.4.10. Rest of Asia Pacific
      • 7.4.10.1. Rest of Asia Pacific Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.10.2. Rest of Asia Pacific Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.10.3. Rest of Asia Pacific Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.4.10.4. Rest of Asia Pacific Insulin Market Revenue, By Indication, 2016 – 2028
  • 7.5. MEA
    • 7.5.1. MEA Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.5.2. MEA Insulin Market Vulume, By Country, 2016 – 2028 (Million Ml)
    • 7.5.3. MEA Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.3.1. MEA Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.3.2. MEA Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
    • 7.5.4. MEA Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.5.5. GCC Countries
      • 7.5.5.1. GCC Countries Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.5.2. GCC Countries Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.5.3. GCC Countries Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.5.4. GCC Countries Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.5.6. South Africa
      • 7.5.6.1. South Africa Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.6.2. South Africa Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.6.3. South Africa Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.6.4. South Africa Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.5.7. Rest of MEA
      • 7.5.7.1. Rest of MEA Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.7.2. Rest of MEA Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.7.3. Rest of MEA Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.5.7.4. Rest of MEA Insulin Market Revenue, By Indication, 2016 – 2028
  • 7.6. Latin America
    • 7.6.1. Latin America Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 7.6.2. Latin America Insulin Market Vulume, By Country, 2016 – 2028 (Million Ml)
    • 7.6.3. Latin America Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.3.1. Latin America Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.3.2. Latin America Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
    • 7.6.4. Latin America Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.6.5. Brazil
      • 7.6.5.1. Brazil Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.5.2. Brazil Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.5.3. Brazil Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.5.4. Brazil Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.6.6. Mexico
      • 7.6.6.1. Mexico Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.6.2. Mexico Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.6.3. Mexico Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.6.4. Mexico Insulin Market Revenue, By Indication, 2016 – 2028
    • 7.6.7. Rest of MEA
      • 7.6.7.1. Rest of MEA Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.7.2. Rest of MEA Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.7.3. Rest of MEA Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
      • 7.6.7.4. Rest of MEA Insulin Market Revenue, By Indication, 2016 – 2028
• CHAPTER NO. 8: INSULIN MARKET (THROUGH EX-FACTORY PRICING)
  • 8.1. Global Insulin Market, 2016-2028, (USD Million), by Region
  • 8.2. North America Insulin Market, 2016-2028, (USD Million), by Country
  • 8.3. Europe Insulin Market, 2016-2028, (USD Million), by Country
  • 8.4. Asia Pacific Insulin Market, 2016-2028, (USD Million), by Country
  • 8.5. Latin America Insulin Market, 2016-2028, (USD Million), by Country
  • 8.6. Middle East & Africa Insulin Market, 2016-2028, (USD Million), by Country
• CHAPTER NO. 9: INSULIN MARKET PRICING ANALYSIS
  • 9.1. Retail Price
    • 9.1.1. North America Pricing, 2016-2028, (USD/Vial), by Country
    • 9.1.2. Europe Insulin Pricing, 2016-2028, (USD/Vial), by Country
    • 9.1.3. Asia Pacific Insulin Pricing, 2016-2028, (USD/Vial), by Country
    • 9.1.4. Latin America Insulin Pricing, 2016-2028, (USD/Vial), by Country
    • 9.1.5. Middle East & Africa Insulin Pricing, 2016-2028, (USD/Vial), by Country
  • 9.2. Ex-Factory Price
    • 9.2.1. North America Pricing, 2016-2028, (USD/Vial), by Country
    • 9.2.2. Europe Insulin Pricing, 2016-2028, (USD/Vial), by Country
    • 9.2.3. Asia Pacific Insulin Pricing, 2016-2028, (USD/Vial), by Country
    • 9.2.4. Latin America Insulin Pricing, 2016-2028, (USD/Vial), by Country
    • 9.2.5. Middle East & Africa Insulin Pricing, 2016-2028, (USD/Vial), by Country
• CHAPTER NO. 10: INSULIN MARKET, BY TYPE (BIOSIMILAR AND BIulOGICS)
  • 10.1. In Terms of USD Million (As per the Retail Price)
    • 10.1.1. North America Insulin Market, 2016-2028, (USD Million), by Type
    • 10.1.2. Europe Insulin Market, 2016-2028, (USD Million), by Type
    • 10.1.3. Asia Pacific Insulin Market, 2016-2028, (USD Million), by Type
    • 10.1.4. MEA Insulin Market, 2016-2028, (USD Million), by Type
    • 10.1.5. Latin America Insulin Market, 2016-2028, (USD Million), by Type
  • 10.2. In Terms of Million Ml (As per the Retail Price)
    • 10.2.1. North America Insulin Market, 2016-2028, (Million Ml), by Type
    • 10.2.2. Europe Insulin Market, 2016-2028, (Million Ml), by Type
    • 10.2.3. Asia Pacific Insulin Market, 2016-2028, (Million Ml), by Type
    • 10.2.4. MEA Insulin Market, 2016-2028, (Million Ml), by Type
    • 10.2.5. Latin America Insulin Market, 2016-2028, (Million Ml), by Type
  • 10.1. In Terms of USD Million (As per the Ex-factory Price)
    • 10.1.1. North America Insulin Market, 2016-2028, (USD Million), by Type
    • 10.1.2. Europe Insulin Market, 2016-2028, (USD Million), by Type
    • 10.1.3. Asia Pacific Insulin Market, 2016-2028, (USD Million), by Type
    • 10.1.4. MEA Insulin Market, 2016-2028, (USD Million), by Type
    • 10.1.5. Latin America Insulin Market, 2016-2028, (USD Million), by Type
  • 10.2. Retail Pricing for Biosimilar and Biulogics
    • 10.2.1. North America Insulin Market, 2016-2028, (USD/Ml), by Type
    • 10.2.2. Europe Insulin Market, 2016-2028, (USD/Ml), by Type
    • 10.2.3. Asia Pacific Insulin Market, 2016-2028, (USD/Ml), by Type
    • 10.2.4. MEA Insulin Market, 2016-2028, (USD/Ml), by Type
    • 10.2.5. Latin America Insulin Market, 2016-2028, (USD/Ml), by Type
  • 10.1. Exfactory Pricing for Biosimilar and Biulogics
    • 10.1.1. North America Insulin Market, 2016-2028, (USD/Ml), by Type
    • 10.1.2. Europe Insulin Market, 2016-2028, (USD/Ml), by Type
    • 10.1.3. Asia Pacific Insulin Market, 2016-2028, (USD/Ml), by Type
    • 10.1.4. MEA Insulin Market, 2016-2028, (USD/Ml), by Type
    • 10.1.5. Latin America Insulin Market, 2016-2028, (USD/Ml), by Type
• CHAPTER NO. 11: INSULIN MARKET PRICING ANALYSIS FOR U.S., U.K AND INDIA
  • 11.1. Ex-Factory Price
    • 11.1.1. U.S. Pricing, 2016-2028, (USD/ml)
      • 11.1.1.1. By Type
      • 11.1.1.2. Rapid-Acting, By Type
      • 11.1.1.3. Long-Acting, by Type
    • 11.1.2. U.K Pricing, 2016-2028, (USD/ml)
      • 11.1.2.1. By Type
      • 11.1.2.2. Rapid-Acting, By Type
      • 11.1.2.3. Long-Acting, by Type
    • 11.1.3. India Pricing, 2016-2028, (USD/ml)
      • 11.1.3.1. By Type
      • 11.1.3.2. Rapid-Acting, By Type
      • 11.1.3.3. Long-Acting, by Type

• 11.2. Retail Price
  • 11.2.1. U.S. Pricing, 2016-2028, (USD/ml)
    • 11.2.1.1. By Type
    • 11.2.1.2. Rapid-Acting, By Type
    • 11.2.1.3. Long-Acting, by Type
  • 11.2.2. U.K Pricing, 2016-2028, (USD/ml)
    • 11.2.2.1. By Type
    • 11.2.2.2. Rapid-Acting, By Type
    • 11.2.2.3. Long-Acting, by Type
  • 11.2.3. India Pricing, 2016-2028, (USD/ml)
    • 11.2.3.1. By Type
    • 11.2.3.2. Rapid-Acting, By Type
    • 11.2.3.3. Long-Acting, by Type
• CHAPTER NO. 12: INSULIN MARKET – INDUSTRY ANALYSIS
  • 12.1. Introduction
  • 12.2. Market Drivers
    • 12.2.1. Rapidly Increasing Prevalence of Diabetes
    • 12.2.2. Lack of Effective Substitute
  • 12.3. Market Restraints
    • 12.3.1. Weak Healthcare System in Low- and Mid-Income Countries
  • 12.4. Market Opportunities
    • 12.4.1. Partner with Local Government to Supply Insulin at Subsidized Prices
  • 12.5. Porter’s Five Forces Analysis
    • 12.5.1. Bargaining Power of Suppliers
    • 12.5.2. Bargaining Power of Buyers
    • 12.5.3. Threat of Substitute
    • 12.5.4. Threat of New Entrants
    • 12.5.5. Competitive Rivalry
  • 12.6. Regulation Pathway
    • 12.6.1. Regulatory Pathways for Biosimilars
  • 12.7. Types and Brands of Insulin
• CHAPTER NO. 13: COMPETITIVE LANDSCAPE
  • 13.1. Company Market Share Analysis, by Regions – 2020
    • 13.1.1. Global Insulin Market, Company Market Revenue, 2020 (% Share)
    • 13.1.2. Global Insulin Market, Company Market Revenue, 2020 (USD Million)
    • 13.1.3. Manufacturing Capacity, by Companies, 2020
    • 13.1.4. Production Share by Companies, 2020
  • 13.2. Key Developments
• CHAPTER NO. 14: COMPANY PROFILES
  • 14.1. Novo Nordisk
    • 14.1.1. Company Description
    • 14.1.2. Operations
    • 14.1.3. Geographic Reach
    • 14.1.4. Financial Performance
    • 14.1.5. Product Information
    • 14.1.6. Strategy
    • 14.1.7. SWOT Analysis
  • 14.2. Eli Lilly & Co.
    • 14.2.1. Company Description
    • 14.2.2. Operations
    • 14.2.3. Geographic Reach
    • 14.2.4. Sales and Marketing
    • 14.2.5. Financial Performance
    • 14.2.6. Product Information
    • 14.2.7. Strategy
    • 14.2.8. Mergers and Acquisitions
  • 14.3. Sanofi
    • 14.3.1. Company Description
    • 14.3.2. Operations
    • 14.3.3. Geographic Reach
    • 14.3.4. Sales and Marketing
    • 14.3.5. Financial Performance
    • 14.3.6. Product Information
    • 14.3.7. Strategy
    • 14.3.8. Mergers and Acquisitions
  • 14.4. Biocon
    • 14.4.1. Company Description
    • 14.4.2. Product Information
• CHAPTER NO. 15: MARKETING STRATEGY ANALYSIS
  • 15.1. Marketing Channel
  • 15.1. Direct Marketing
  • 15.2. Indirect Marketing
  • 15.3. Marketing Channel Development Trends
• CHAPTER NO. 16: RESEARCH METHODulOGY
  • 16.1. Research Methodulogy
  • 16.2. Phase I - Secondary Research
  • 16.3. Phase II - Data Modeling
    • 16.3.1. Company Share Analysis Model
    • 16.3.2. Revenue Based Modeling
  • 16.4. Phase III - Primary Research

Table Of Figures

List of Figures    

FIG NO. 1. Market Revenue Share, By Type, 2020 & 2028
FIG NO. 2. Global Insulin Market for Rapid-Acting, Revenue (USD Million) 2016 – 2028
FIG NO. 3. Global Insulin Market for Short-Acting, Revenue (USD Million) 2016 – 2028
FIG NO. 4. Global Insulin Market for Intermediate -Acting, Revenue (USD Million) 2016 – 2028
FIG NO. 5. Global Insulin Market for Long-Acting, Revenue (USD Million) 2016 – 2028
FIG NO. 6. Global Insulin Market for Premixed, Revenue (USD Million) 2016 – 2028
FIG NO. 7. Market Revenue Share, By Type, 2020 & 2028
FIG NO. 8. Global Insulin Market for Glulisine, Revenue (USD Million) 2016 – 2028
FIG NO. 9. Global Insulin Market for Lispro, Revenue (USD Million) 2016 – 2028
FIG NO. 10. Global Insulin Market for Aspart, Revenue (USD Million) 2016 – 2028
FIG NO. 11. Market Revenue Share, By Type, 2020 & 2028
FIG NO. 12. Global Insulin Market for Glargine, Revenue (USD Million) 2016 – 2028
FIG NO. 13. Global Insulin Market for Detemir, Revenue (USD Million) 2016 – 2028
FIG NO. 14. Market Revenue Share, By Indication, 2020 & 2028
FIG NO. 15. Global Insulin Market for Type 1, Revenue (USD Million) 2016 – 2028
FIG NO. 16. Global Insulin Market for Type 2, Revenue (USD Million) 2016 – 2028
FIG NO. 17. Global Insulin Market Revenue Share, By Region, 2020 & 2028
FIG NO. 18. Global Insulin Market Volume Share, By Region, 2020 & 2028
FIG NO. 19. Research Methodology – Detailed View
FIG NO. 20. Research Methodology

Table Of Tables

List of Tables 

TABLE NO. 1: Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
TABLE NO. 2: Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
TABLE NO. 3: Global Insulin Market Volume, By Region, 2016 – 2028 (USD Million)
TABLE NO. 4: Global Insulin Market Volume, By Region, 2016 – 2028 (Million Ml)
TABLE NO. 5: North America Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 6: North America Insulin Market Volume, By Country, 2016 – 2028 (Million Ml)
TABLE NO. 7: North America Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 8: North America Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 9: North America Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 10: North America Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 11: U.S. Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 12: U.S. Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 13: U.S. Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 14: U.S. Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 15: Canada Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 16: Canada Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 17: Canada Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 18: Canada Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 19: Europe Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 20: Europe Insulin Market Volume, By Country, 2016 – 2028 (Million Ml)
TABLE NO. 21: Europe Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 22: Europe Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 23: Europe Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 24: Europe Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 25: Germany Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 26: Germany Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 27: Germany Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 28: Germany Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 29: France Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 30: France Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 31: France Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 32: France Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 33: U.K Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 34: U.K Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 35: U. K Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 36: U.K Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 37: Italy Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 38: Italy Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 39: Italy Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 40: Italy Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 41: Spain Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 42: Spain Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 43: Spain Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 44: Spain Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 45: Rest of Europe Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 46: Rest of Europe Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 47: Rest of Europe Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 48: Rest of Europe Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 49: Asia Pacific Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 50: Asia Pacific Insulin Market Volume, By Country, 2016 – 2028 (Million Ml)
TABLE NO. 51: Asia Pacific Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 52: Asia Pacific Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 53: Asia Pacific Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 54: Asia Pacific Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 55: China Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 56: China Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 57: China Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 58: China Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 59: Korea Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 60: Korea Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 61: Korea Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 62: Korea Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 63: India Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 64: India Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 65: India Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 66: India Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 67: Japan Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 68: Japan Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 69: Japan Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 70: Japan Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 71: Southeast Asia Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 72: Southeast Asia Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 73: Southeast Asia Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 74: Southeast Asia Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 75: Rest of Asia Pacific Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 76: Rest of Asia Pacific Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 77: Rest of Asia Pacific Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 78: Rest of Asia Pacific Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 79: MEA Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 80: MEA Insulin Market Volume, By Country, 2016 – 2028 (Million Ml)
TABLE NO. 81: MEA Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 82: MEA Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 83: MEA Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 84: MEA Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 85: GCC Countries Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 86: GCC Countries Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 87: GCC Countries Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 88: GCC Countries Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 89: South Africa Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 90: South Africa Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 91: South Africa Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 92: South Africa Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 93: Rest of MEA Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 94: Rest of MEA Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 95: Rest of MEA Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 96: Rest of MEA Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 97: Latin America Insulin Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 98: Latin America Insulin Market Volume, By Country, 2016 – 2028 (Million Ml)
TABLE NO. 99: Latin America Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 100: Latin America Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 101: Latin America Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 102: Latin America Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 103: Brazil Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 104: Brazil  Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 105: Brazil Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 106: Brazil Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 107: Mexico Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 108: Mexico Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 109: Mexico Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 110: Mexico Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 111: Rest of MEA Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 112: Rest of MEA Rapid Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 113: Rest of MEA Long Acting Insulin Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 114: Rest of MEA Insulin Market Revenue, By Indication, 2016 – 2028 (USD Million)
TABLE NO. 115: Drivers for the Insulin Market: Impact Analysis